Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given voluntary written consent to participate before any screening begins.
• People aged 18 or older, of any gender.
• People whose general health and ability to carry out daily activities is rated at a good to nearly-full level (a score of 0 or 1 on a standard medical scale used in cancer research).
• People whose expected survival is at least 3 months.
• People who have been confirmed through laboratory testing of tissue or cell samples to have advanced or metastatic non-small cell lung cancer (a type of lung cancer) that cannot be fully removed by surgery and is not suitable for a combined radiation and chemotherapy treatment approach, staged according to a specific international cancer staging system.
• People with certain types of lung cancer (adenocarcinoma, those who have never smoked, or squamous cell carcinoma with mixed features) who have been confirmed — through tissue, cell, or blood testing — to not have specific gene changes (EGFR mutations or ALK rearrangements) known to affect treatment choice.
• People who can provide a tumour tissue sample for a specific protein test (PD-L1 testing).
• People who have not previously received any systemic cancer treatment for this condition.
• People who have at least one measurable area of cancer (not counting any in the brain) based on standard imaging measurement criteria.
• People whose organ function meets the required levels as assessed by the trial site (confirm specific thresholds with trial site).

Who may not be able to join:

• People whose cancer has specific gene changes (ROS1 fusion, BRAF V600E mutation, or other driver mutations) for which standard first-line targeted treatments are recommended.
• People who have previously received radiation therapy to the chest area.
• People who have cancer spread to the brain that is currently causing symptoms.
• People whose scans show the tumour is growing into major blood vessels, critical nearby organs, or poses a risk of creating an abnormal connection between the oesophagus and the airway or lung lining, as assessed by the medical team.
• People with a history of severe high blood pressure crises or high-blood-pressure-related brain complications, or whose blood pressure cannot be controlled with medication.
• People with an active autoimmune disease (where the immune system attacks the body's own tissues), or a history of one that could return.
• People with a tendency to bleed easily, a high risk of bleeding, or a blood clotting disorder.
• People with another current or recent cancer diagnosis.
• People with a serious active infection before the first dose, including active tuberculosis, HIV, active hepatitis B or C, or active syphilis.
• People with significant fluid build-up around the lungs, heart, or abdomen that requires repeated draining.
• People with a history of lung inflammation (non-infectious pneumonitis) that required steroid treatment, or who currently have a chronic scarring lung condition (interstitial lung disease).
• People who have previously received an organ transplant or a stem cell transplant from another person.
• People with a known allergy to any ingredient in the study drug(s), or a history of a severe allergic reaction to any antibody-based medicine.
• People currently taking part in another clinical trial (observational studies or follow-up phases of previous trials may be exceptions — confirm with trial site).
• People who are pregnant or breastfeeding.
• People with known alcohol or drug dependence, psychiatric conditions, or a history of illicit drug use.
• People who the trial medical team considers unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.